About Kelun Botai Bio-B

Sichuan Kelun Biotech Co., Ltd. (hereinafter referred to as "Kelun Biotech" or "the Company") is a biopharmaceutical company focusing on the research, development, manufacturing and commercialization of innovative drugs. Since its establishment in 2016, it has been committed to addressing medical needs in China and around the world. With integrated drug development capabilities and a sound management mechanism covering all key business functions, Kelun Biotech is committed to developing differentiated treatments in-house to support the improvement of existing medical health levels. As one of the pioneers and leading developers of antibody-drug conjugates (ADCs), Kelun Biotech has accumulated more than ten years of experience in ADC development and is one of the first and few biopharmaceutical companies in China to establish an integrated ADC R&D platform, OptiDC. The Company adopts a systematic, indication-oriented approach to address the world's common or difficult-to-treat cancers and other diseases and conditions with a large patient population and unmet medical needs. Over the years, the Company has established integrated capabilities covering all major drug development functions, including R&D, production, quality control and commercialization, and is able to strategically and rapidly advance a pipeline of 33 differentiated and clinically valuable assets, 14 of which are in the clinical stage. Supported by three self-developed technology platforms, Kelun Biotech has proprietary technologies in ADC, macromolecules (monoclonal antibodies (mAbs) and bispecific antibodies (bAbs) and small molecule drugs, which have been verified by many of the company's clinical-stage drug candidates. The company has built a strong pipeline that is diverse and synergistic in terms of drug modalities, mechanisms and indications. The decades of experience, industry relationships and extensive network of the controlling shareholder Kelun Pharmaceutical have created good conditions for Kelun Biotech to expand its commercialization infrastructure and market channels. At the same time, Kelun Biotech's pipeline clinical value and drug development capabilities have also been recognized by global strategic partners. To date, the company has signed nine out-licensing agreements, including one with Merck Sharp & Dohme LLC (together with its affiliates, "Merck"), has entered into three licensing and collaboration agreements to develop up to nine ADC assets for cancer treatment, with upfront and milestone payments totaling up to $11.8 billion. These strategic collaborations not only demonstrate the company's R&D and business development capabilities, but are also key drivers of continued innovation, building global influence and long-term growth. Looking ahead, Kelun Biotech will strive to advance pipeline commercialization and enhance integrated drug development capabilities, continue to lead the R&D and clinical activities of candidate drugs, and strive to optimize R&D platforms and develop new technologies to support the development of innovative drugs. Kelun Biotech will also continue to expand cGMP production and quality control facilities and enhance internal commercialization capabilities to support the future launch of pipeline assets and achieve the goal of becoming a leading global biopharmaceutical company.